Quench Bio
Quench Bio is a Cambridge, Massachusetts-based preclinical biotechnology company founded in 2018 that develops therapeutics targeting gasdermin biology to treat severe inflammatory diseases, backed by RA Capital, AbbVie, Arix, and Atlas.
- Company typePrivate
- Founded2018
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Quench Bio does
Quench Bio is a Cambridge, Massachusetts-based biotechnology company founded in 2018 that develops therapeutics targeting gasdermin biology — a pathway governing pyroptotic cell death and inflammatory cytokine release — to treat severe inflammatory diseases. The company's scientific premise is that selective modulation of gasdermin-mediated inflammatory cell death could address indications underserved by conventional anti-inflammatory and immunosuppressive approaches. The company's platform and pipeline details, including specific lead candidates and target indications beyond "severe inflammatory diseases," are not disclosed in the available data.
On the business side, Quench Bio has operated as a private, venture-backed preclinical-stage biotech. The company closed a $50 million Series A in January 2020 led by RA Capital Management with AbbVie, Arix Bioscience, and Atlas Venture participating, after initial formation backing from Arix Bioscience and Atlas Venture in 2018. Quench Bio has never disclosed commercial product revenue, partnership economics, or licensing income; its capital structure is consistent with a research-stage entity financed almost entirely by equity. The firm has no disclosed manufacturing, commercial, or distribution infrastructure and operates with 1-10 employees.
Operating-status signals are negative. The company's primary web domain, quenchbio.com, is listed for sale on HugeDomains at $12,795, and the aggregated data flags operating status as "closed." Combined with the absence of any disclosed follow-on financing, pipeline advancement, partnership, or hiring since the 2020 Series A, this pattern is consistent with a wind-down, dormancy, or asset-sale trajectory rather than active commercial development.
Quench Bio firmographics
Firmographics- Name
- Quench Bio
- Website
- https://quenchbio.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Closed
- Headcount range
- 1–10 employees
- Short description
- Quench Bio is a Cambridge, Massachusetts-based preclinical biotechnology company founded in 2018 that develops therapeutics targeting gasdermin biology to treat severe inflammatory diseases, backed by RA Capital, AbbVie, Arix, and Atlas.
- Ownership category
- akta.pro rank
Quench Bio industry classification
Industry- Product category
- Inflammatory Disease Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industry
- In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)
Keywords
Where Quench Bio is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Quench Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Monthly | Domain purchase - one-time payment |
Quench Bio product offering
Product offeringCore offering
Quench Bio is a developer of gasdermin biology drugs intended for the treatment of severe inflammatory diseases. The company is engaged in biopharmaceutical drug discovery, building a pipeline of therapeutics that target gasdermin-mediated inflammatory pathways.
Differentiator
Problem solved
Functional benefit
Companies that use Quench Bio
Customer profileIdeal customer profiles1 record
Quench Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Quench Bio partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights4 records
Quench Bio competitors and assessment
Company assessmentDirect peers
- Inflazome: Developed small-molecule NLRP3 inflammasome inhibitors targeting the same pyroptosis/inflammation biology as Quench Bio's gasdermin D programs. Acquired by Roche in 2020, validating pharma demand for this mechanistic class.
- IFM Tre: IFM Therapeutics' subsidiary developed a small-molecule NLRP3 antagonist (IFM-2427) for inflammatory diseases. Acquired by Novartis in 2019; directly comparable to Quench Bio's inflammasome/pyroptosis thesis.
- NodThera: UK- and US-based biotech developing small-molecule NLRP3 inflammasome inhibitors for inflammatory and neuroinflammatory diseases. Competes with Quench Bio for the same pharma BD and scientific positioning.
- Olatec Therapeutics: Clinical-stage developer of dapansutrile, an oral NLRP3 inhibitor. Addresses overlapping inflammasome-mediated inflammatory disease indications as Quench Bio's gasdermin D program.
Emerging players
- ZyVersa Therapeutics: Focused on inflammasome pathway inhibition, including IC 100, an inflammasome ASC inhibitor. Operates in adjacent inflammasome biology with similar target rationale to Quench Bio.
- Ventus Therapeutics: Structure-based drug discovery company developing small molecules against innate immune targets, including inflammasome components. Comparable in stage and platform-driven approach to a gasdermin D program.
- GenFleet Therapeutics: China-based clinical-stage biotech with disclosed gasdermin D inhibitor programs, directly addressing the same novel target as Quench Bio and representing the closest mechanistic competitor.
Broad incumbents
- Novartis: Acquired IFM Tre and built a leading inflammasome/pyroptosis portfolio. Broad incumbent in immunology with the resources to outcompete small players like Quench Bio on clinical translation and BD.
- Roche: Acquired Inflazome in 2020 to anchor its NLRP3/inflammasome strategy; comparable broad incumbent pursuing the same upstream inflammation biology as Quench Bio.
- AbbVie: Major immunology incumbent and a direct investor in Quench Bio's 2020 Series A; comparable as both a strategic with overlapping inflammation franchise (Humira/Skyrizi/Rinvoq) and as a counterparty likely to evaluate gasdermin assets.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key risks4 records
Key highlights3 records
Customer concentration
Quench Bio social profiles
Digital presenceQuench Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quench Bio leadership team
Management profileNumber of profiles
Profiles1 record
Quench Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quench Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quench Bio
What does Quench Bio do?
Quench Bio is a developer of gasdermin biology drugs intended for the treatment of severe inflammatory diseases. The company is engaged in biopharmaceutical drug discovery, building a pipeline of therapeutics that target gasdermin-mediated inflammatory pathways.
Is Quench Bio a public or private company?
Quench Bio is a private company. It is classified as venture growth investor backed and is currently closed.
When was Quench Bio founded?
Quench Bio was founded in 2018. It employs 1 to 10 people.
Where is Quench Bio based?
Quench Bio is headquartered in Cambridge, United States, in the North America region.
Who are Quench Bio's main competitors?
Direct peers on record are Inflazome, IFM Tre, NodThera and Olatec Therapeutics. Emerging players are ZyVersa Therapeutics, Ventus Therapeutics and GenFleet Therapeutics. Broad incumbents are Novartis, Roche and AbbVie.
Does Quench Bio have an API?
No public API is recorded for Quench Bio.
What industry is Quench Bio in?
Quench Bio's product category is Inflammatory Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy). Its NAICS code is 541714 and its SIC code is 2833.